All Stories

  1. Metabolome alterations in pediatric metabolically unhealthy obesity are primarily linked to abnormal glucose homeostasis
  2. Evaluation of Four Semi‐Mechanistic Models for Predicting Glycemic Control With a Glucagon Receptor Antagonist in People With Type 2 Diabetes
  3. Comment on “Ticagrelor is Associated with Increased Rosuvastatin Blood Concentrations in Patients Who Have Had a Myocardial Infarction”
  4. Development of Embryonic Stem Cell-derived Human Cardiomyocytes and Application of Fluorescence Probe Substrate for Characterization of CYP2J2
  5. Catalytic difluorocarbene insertion enables access to fluorinated oxetane isosteres
  6. Developing Mitigation Measures for Full or Partially Missed Nirmatrelvir-Ritonavir Doses using Physiologically-Based Pharmacokinetic Modelling
  7. Elucidating the Phase I metabolism of psilocin in vitro
  8. Application of physiologically‐based pharmacokinetic modeling to inform dosing decisions for geriatric patients
  9. Ex vivo metabolism kinetics of primary to secondary bile acids via a physiologically relevant human faecal microbiota model
  10. Physiologically‐based pharmacokinetic modelling guided dose evaluations of nirmatrelvir/ritonavir in renal impairment for the management of COVID‐19
  11. Probe Substrate Dependencies in CYP3A4 Allosteric Inhibition: A Novel Molecular Mechanism Involving F–F′ Loop Perturbations
  12. Predictors associated with bleeding and thromboembolic complications in patients taking rivaroxaban-- a Singapore study
  13. Ciprofol is primarily glucuronidated by UGT1A9 and predicted not to cause drug-drug interactions with typical substrates of CYP1A2, CYP2B6, and CYP2C19
  14. Investigating the relevance of CYP2J2 inhibition for drugs known to cause intermediate to high risk torsades de pointes
  15. Risk assessment of cultured meat
  16. Unraveling Complexities in the Absorption and Disposition Kinetics of Abiraterone via Iterative PBPK Model Development and Refinement
  17. Role of Cytochrome P450 2C8 in Drug–Drug Interaction between Amiodarone and Nirmatrelvir/Ritonavir Via Physiologically‐Based Pharmacokinetic Modeling
  18. Development and verification of a physiologically‐based pharmacokinetic model of dronedarone and its active metabolite N‐desbutyldronedarone: application to prospective simulation of complex drug‐drug interaction with rivaroxaban.
  19. Lactobacillus paracasei IMC 502 ameliorate type 2 diabetes by mediating gut microbiota‐SCFAs ‐hormone/inflammation pathway in mice
  20. Identification of Optimal Urinary Biomarkers of Synthetic Cannabinoids BZO-HEXOXIZID, BZO-POXIZID, 5F-BZO-POXIZID, and BZO-CHMOXIZID for Illicit Abuse Monitoring
  21. Inhibition of cytochrome P450 2J2-mediated metabolism of rivaroxaban and arachidonic acid by ibrutinib and osimertinib
  22. Physiologically Based Pharmacokinetic Modelling‐Guided Dose Management of Oral Anticoagulants when Initiating Paxlovid for COVID ‐19 Treatment
  23. Identification of Infigratinib as a Potent Reversible Inhibitor and Mechanism-Based Inactivator of CYP2J2: Nascent Evidence for a Potential In Vivo Metabolic Drug-Drug Interaction with Rivaroxaban
  24. Simvastatin, but Not Atorvastatin, Is Associated with Higher Peak Rivaroxaban Serum Levels and Bleeding: an Asian Cohort Study from Singapore
  25. Metabolic Activation of the Acrylamide Michael Acceptor Warhead in Futibatinib to an Epoxide Intermediate Engenders Covalent Inactivation of Cytochrome P450 3A
  26. Quantification of the irreversible fibroblast growth factor receptor inhibitor futibatinib by UPLC-MS/MS: Application to the metabolic stability assay in human liver microsomes for the estimation of its in vitro hepatic intrinsic clearance
  27. Rational deuteration of dronedarone attenuates its toxicity in human hepatic HepG2 cells
  28. Site-directed deuteration of dronedarone preserves cytochrome P4502J2 activity and mitigates its cardiac adverse effects in canine arrhythmic hearts
  29. Direct and Sequential Bioactivation of Pemigatinib to Reactive Iminium Ion Intermediates Culminate in Mechanism-Based Inactivation of Cytochrome P450 3A
  30. Antidiabetic effects of multi-species probiotic and its fermented milk in mice via restoring gut microbiota and intestinal barrier
  31. Febuxostat and its Major Acyl Glucuronide Metabolite are Potent Inhibitors of Organic Anion Transporter 3: Implications for Drug‐Drug Interactions with Rivaroxaban
  32. Transesterification of Indazole-3-Carboxamide Synthetic Cannabinoids: Identification of Metabolite Biomarker for Diagnosing Co-Abuse of 5F-MDMB-PINACA and Alcohol
  33. Inhibition of cytochrome P450 enzymes and uridine 5′-diphospho-glucuronosyltransferases by vicagrel in human liver microsomes: A prediction of potential drug-drug interactions
  34. Application of a PBPK Model of Rivaroxaban to Prospective Simulations of Drug‐Drug‐Disease Interactions with Protein Kinase Inhibitors in CA‐VTE
  35. Model-Based Risk Prediction of Rivaroxaban with Amiodarone for Moderate Renal Impaired Elderly Population
  36. Atypical kinetics of cytochrome P450 2J2: Epoxidation of arachidonic acid and reversible inhibition by xenobiotic inhibitors
  37. Urinary Metabolite Biomarkers for the Detection of Synthetic Cannabinoid ADB-BUTINACA Abuse
  38. Preliminary discovery of novel markers for human cell line activation test (h-CLAT)
  39. Infigratinib Is a Reversible Inhibitor and Mechanism-Based Inactivator of Cytochrome P450 3A4
  40. Differential Reversible and Irreversible Interactions between Benzbromarone and Human Cytochrome P450s 3A4 and 3A5
  41. Mechanism-Based Inactivation of Cytochrome P450 3A4 and 3A5 by the Fibroblast Growth Factor Receptor Inhibitor Erdafitinib
  42. Investigation of the arcane inhibition of human organic anion transporter 3 by benzofuran antiarrhythmic agents
  43. Fructose intolerance is not associated with malabsorption in patients with functional gastrointestinal disorders
  44. Mechanism-based Inactivation of Cytochrome P450 3A4 by Benzbromarone
  45. An exploratory analysis of effects of poyendarone, a deuterated analogue of dronedarone, on the canine model of paroxysmal atrial fibrillation
  46. Diagnosing intake and rationalizing toxicities associated with 5F-MDMB-PINACA and 4F-MDMB-BINACA abuse
  47. A compromised developmental trajectory of the infant gut microbiome and metabolome in atopic eczema
  48. Tryptophan–kynurenine ratio as a biomarker of bladder cancer
  49. Combination Bacillus Calmette-Guérin and indoleamine 2,3-dioxygenase 1 inhibitor therapy of murine orthotopic bladder cancer
  50. Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen
  51. Increased Protein S-Glutathionylation in Leber’s Hereditary Optic Neuropathy (LHON)
  52. How the Deuteration of Dronedarone Can Modify Its Cardiovascular Profile: In Vivo Characterization of Electropharmacological Effects of Poyendarone, a Deuterated Analogue of Dronedarone
  53. Predicting human tissue exposures to xenobiotics using a bottom-up physiologically-based biokinetic model
  54. Atypical Michaelis-Menten kinetics in cytochrome P450 enzymes: A focus on substrate inhibition
  55. Systematic Development and Verification of a Physiologically Based Pharmacokinetic Model of Rivaroxaban
  56. Bottom-up physiologically-based biokinetic modelling as an alternative to animal testing
  57. Faculty cooperation in teaching academic literacy using popular science texts: A case study
  58. Dose-Dependent Increase in Unconjugated Cinnamic Acid Concentration in Plasma Following Acute Consumption of Polyphenol Rich Curry in the Polyspice Study
  59. Reactive Metabolite-induced Protein Glutathionylation: A Potentially Novel Mechanism Underlying Acetaminophen Hepatotoxicity
  60. Rivaroxaban With and Without Amiodarone in Renal Impairment
  61. Recent advances in the applications of metabolomics in eye research
  62. Dronedarone-Induced Cardiac Mitochondrial Dysfunction & Its Mitigation by Epoxyeicosatrienoic Acids
  63. Polyphenol-rich curry made with mixed spices and vegetables benefits glucose homeostasis in Chinese males (Polyspice Study): a dose–response randomized controlled crossover trial
  64. Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine
  65. Effects of dronedarone, amiodarone and their active metabolites on sequential metabolism of arachidonic acid to epoxyeicosatrienoic and dihydroxyeicosatrienoic acids
  66. The liver-gut microbiota axis modulates hepatotoxicity of tacrine in the rat
  67. In Silico and in Vitro Interactions between Short Chain Fatty Acids and Human Histone Deacetylases
  68. Inhibition and inactivation of human CYP2J2: Implications in cardiac pathophysiology and opportunities in cancer therapy
  69. A novel LCMSMS method for quantitative measurement of short-chain fatty acids in human stool derivatized with 12 C- and 13 C-labelled aniline
  70. Common deregulated gene expression profiles and morphological changes in developing zebrafish larvae exposed to environmental-relevant high to low concentrations of glucocorticoids
  71. Application of Static Modeling ­­in the Prediction of In Vivo Drug–Drug Interactions between Rivaroxaban and Antiarrhythmic Agents Based on In Vitro Inhibition Studies
  72. Proteo-metabolomics in elucidating mechanisms of acetaminophen toxicity
  73. Targeted LC/MS-based quantitative profiling of 15 gut microbiome-derived short chain fatty acids in infant and adult stool
  74. Dronedarone inhibits CYP2J3 activity in H9c2 cardiomyocytes without mitochondrial toxicity
  75. Synergistic disruption of ERα/HER2 crosstalk by endoxifen and lapatinib in breast cancer cells
  76. Evaluating Polymyxin B-Based Combinations against Carbapenem-Resistant Escherichia coli in Time-Kill Studies and in a Hollow-Fiber Infection Model
  77. In VitroActivity of Polymyxin B in Combination with Various Antibiotics against Extensively Drug-Resistant Enterobacter cloacae with Decreased Susceptibility to Polymyxin B
  78. Phase I Metabolic Stability and Electrophilic Reactivity of 2-Phenylaminophenylacetic Acid Derived Compounds
  79. Multiple modes of inhibition of human cytochrome P450 2J2 by dronedarone, amiodarone and their active metabolites
  80. Metabolomic Characterizations of Liver Injury Caused by Acute Arsenic Toxicity in Zebrafish
  81. Metabolic Markers for Diabetic Retinopathy
  82. The Isotope-Coded Affinity Tag Method for Quantitative Protein Profile Comparison and Relative Quantitation of Cysteine Redox Modifications
  83. Metabonomic diagnosis of bladder cancer: what are the advantages and considerations?
  84. Gastrointestinal Symptoms and Altered Intestinal Permeability Induced by Combat Training Are Associated with Distinct Metabotypic Changes
  85. Inactivation of Human Cytochrome P450 3A4 and 3A5 by Dronedarone and N-Desbutyl Dronedarone
  86. Understanding the cholesterol metabolism-perturbing effects of docosahexaenoic acid by gas chromatography–mass spectrometry targeted metabonomic profiling
  87. Meclizine, a pregnane X receptor agonist, is a direct inhibitor and mechanism-based inactivator of human cytochrome P450 3A
  88. Global Metabonomic and Proteomic Analysis of Human Conjunctival Epithelial Cells (IOBA-NHC) in Response to Hyperosmotic Stress
  89. Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer
  90. Investigation of Host–Gut Microbiota Modulation of Therapeutic Outcome
  91. In VitroPharmacodynamics of Various Antibiotics in Combination against Extensively Drug-Resistant Klebsiella pneumoniae
  92. Metabolic Profiling of CHO-AβPP695 Cells Revealed Mitochondrial Dysfunction Prior to Amyloid-β Pathology and Potential Therapeutic Effects of Both PPARγ and PPARα Agonisms for Alzheimer's Disease
  93. Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib
  94. Metabonomic Profiling of Bladder Cancer
  95. Global fecal microRNA profiling in the identification of biomarkers for colorectal cancer screening among Asians
  96. Metabotyping of Docosahexaenoic Acid - Treated Alzheimer’s Disease Cell Model
  97. Development of an UPLC–MS/MS method for assaying the enzymatic activity of propionyl coenzyme-A carboxylase
  98. Non-invasive fecal metabonomic detection of colorectal cancer
  99. Applications of monolithic materials for sample preparation
  100. Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model
  101. Global gas chromatography/time-of-flight mass spectrometry (GC/TOFMS)-based metabonomic profiling of lyophilized human feces
  102. Urinary Metabotyping of Bladder Cancer Using Two-Dimensional Gas Chromatography Time-of-Flight Mass Spectrometry
  103. Metabolically Functional Hepatocyte-Like Cells from Human Umbilical Cord Lining Epithelial Cells
  104. An automated Pearson's correlation change classification (APC3) approach for GC/MS metabonomic data using total ion chromatograms (TICs)
  105. Gas Chromatography/Mass Spectrometry-Based Metabonomics
  106. Investigating the role of nucleoside transporters in the resistance of colorectal cancer to 5-fluorouracil therapy
  107. Pyrrolidinediones reduce the toxicity of thiazolidinediones and modify their anti-diabetic and anti-cancer properties
  108. Optimizing hollow-fiber-based pharmacokinetic assay via chemical stability study to account for inaccurate simulated drug clearance of rifampicin
  109. Metabonomic Profiling of TASTPM Transgenic Alzheimer’s Disease Mouse Model
  110. An Investigation of the Bioactivation Potential and Metabolism Profile of Zebrafish versus Human
  111. LC-MS-based metabolic characterization of high monoclonal antibody-producing Chinese hamster ovary cells
  112. Thomas O. Metz (Ed.): Metabolic profiling. Methods and protocols
  113. Interaction of Lapatinib with Cytochrome P450 3A5
  114. ChemInform Abstract: Trend Analysis of Metabonomics and Systematic Review of Metabonomics-derived Cancer Marker Metabolites
  115. Metabotyping of human colorectal cancer using two-dimensional gas chromatography mass spectrometry
  116. Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence
  117. Metabonomics
  118. Reversible time-dependent inhibition of cytochrome P450 enzymes by duloxetine and inertness of its thiophene ring towards bioactivation
  119. Global urinary metabolic profiling procedures using gas chromatography–mass spectrometry
  120. Efficiency of a miniaturized silica monolithic cartridge in reducing matrix ions as demonstrated in the simultaneous extraction of morphine and codeine from urine samples for quantification with liquid chromatography-tandem mass spectrometry (LC-MS/MS)
  121. Characterization of The Human Tear Metabolome by LC–MS/MS
  122. Use of Urine Volatile Organic Compounds To Discriminate Tuberculosis Patients from Healthy Subjects
  123. Metabolic Profiling of 3-Nitropropionic Acid Early-Stage Huntington’s Disease Rat Model Using Gas Chromatography Time-of-Flight Mass Spectrometry
  124. Extraction of ketamine from urine using a miniature silica monolithic cartridge followed by quantification with liquid chromatography tandem mass spectrometry (LC-MS/MS)
  125. Metabolic Intermediate Complex Formation of Human Cytochrome P450 3A4 by Lapatinib
  126. Zebrafish for drug toxicity screening: bridging thein vitrocell-based models andin vivomammalian models
  127. Ultra-pressure liquid chromatography/tandem mass spectrometry targeted profiling of arachidonic acid and eicosanoids in human colorectal cancer
  128. Anti-proliferative effects of raw and steamed extracts of Panax notoginseng and its ginsenoside constituents on human liver cancer cells
  129. Comparative evaluation of software for retention time alignment of gas chromatography/time-of-flight mass spectrometry-based metabonomic data
  130. Trend analysis of metabonomics and systematic review of metabonomics-derived cancer marker metabolites
  131. Metabolic footprinting of tumorigenic and nontumorigenic uroepithelial cells using two-dimensional gas chromatography time-of-flight mass spectrometry
  132. Mechanism-Based Inactivation of Cytochrome P450 3A4 by Lapatinib
  133. On-line chromatographic screening of matrix metalloproteinase inhibitors using immobilized MMP-9 enzyme reactor
  134. Application of silica-based monolith as solid phase extraction cartridge for extracting polar compounds from urine
  135. Direct toxicity effects of sulfo-conjugated troglitazone on human hepatocytes
  136. Ultra-high performance liquid chromatography/time-of-flight mass spectrometry (UHPLC/TOFMS) for time-dependent profiling of raw and steamed Panax notoginseng
  137. Noninvasive Urinary Metabonomic Diagnosis of Human Bladder Cancer
  138. Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity
  139. A sensitive LC/MS/MS bioanalysis assay of orally administered lipoic acid in rat blood and brain tissue
  140. Fluorescence-Based Liver Microsomal Assay for Screening of Pharmaceutical Reactive Metabolites Using a Glutathione Conjugated 96-Well Plate
  141. Metabolic Profiling of Rat Brain and Cognitive Behavioral Tasks: Potential Complementary Strategies in Preclinical Cognition Enhancement Research
  142. Underlying mitochondrial dysfunction triggers flutamide-induced oxidative liver injury in a mouse model of idiosyncratic drug toxicity
  143. Development and validation of a gas chromatography/mass spectrometry method for the metabolic profiling of human colon tissue
  144. Pharmaceutical metabolite profiling using quadrupole/ion mobility spectrometry/time-of-flight mass spectrometry
  145. Distribution study of orally administered lipoic acid in rat brain tissues
  146. Metabolic Profiling of Human Colorectal Cancer Using High-Resolution Magic Angle Spinning Nuclear Magnetic Resonance (HR-MAS NMR) Spectroscopy and Gas Chromatography Mass Spectrometry (GC/MS)
  147. Development and validation of a gas chromatography/mass spectrometry metabonomic platform for the global profiling of urinary metabolites
  148. Metabonomics investigation of human urine after ingestion of green tea with gas chromatography/mass spectrometry, liquid chromatography/mass spectrometry and1H NMR spectroscopy
  149. Oxidative Bioactivation and Toxicity of Leflunomide in Immortalized Human Hepatocytes and Kinetics of the Non-Enzymatic to Its Major etabolitie, A77 1726
  150. Prevention of acetaminophen (APAP)-induced hepatotoxicity by leflunomide via inhibition of APAP biotransformation to N-acetyl-p-benzoquinone imine
  151. Gas chromatography/mass spectrometry in metabolic profiling of biological fluids
  152. Investigation of the Drug–Drug Interaction Between α-Lipoic Acid and Valproate via Mitochondrial β-oxidation
  153. Bonding interfaces in wafer-level metal/adhesive bonded 3D integration
  154. Evaluation of BEH C18, BEH HILIC, and HSS T3 (C18) Column Chemistries for the UPLC-MS-MS Analysis of Glutathione, Glutathione Disulfide, and Ophthalmic Acid in Mouse Liver and Human Plasma
  155. Enhancing pharmaceutical analysis laboratory classes via the measurement of minerals in Berocca® effervescent tablets
  156. In Vitro Metabolism of Leflunomide by Mouse and Human Liver Microsomes
  157. Pharmacokinetic study of intraperitoneally administered troglitazone in mice using ultra-performance liquid chromatography/tandem mass spectrometry
  158. Ultra-performance liquid chromatography/time-of-flight mass spectrometry based metabolomics of raw and steamedPanax notoginseng
  159. Detection of aristolochic acid I, tetrandrine and fangchinoline in medicinal plants by high performance liquid chromatography and liquid chromatography/mass spectrometry
  160. Modeling Caco-2 permeability of drugs using immobilized artificial membrane chromatography and physicochemical descriptors
  161. Hydrophilic interaction liquid chromatography with tandem mass spectrometry for the determination of underivatized dencichine (β-N-oxalyl-L-α,β-diaminopropionic acid) inPanax medicinal plant species
  162. Application of Visual Basic in High-Throughput Mass Spectrometry-Directed Purification of Combinatorial Libraries
  163. Preparation and characterization of immunogens for antibody production against metanephrine and normetanephrine
  164. An automated LC method for the small-scale purification of organic molecules derived from combinatorial libraries
  165. Evaluation of degradation of urinary catecholamines and metanephrines and deconjugation of their sulfoconjugates using stability-indicating reversed-phase ion-pair HPLC with electrochemical detection
  166. High-performance liquid chromatographic assay for catecholamines and metanephrines using fluorimetric detection with pre-column 9-fluorenylmethyloxycarbonyl chloride derivatization
  167. High-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometric method for the analysis of catecholamines and metanephrines in human urine
  168. The value of analytical assays that are stability-indicating
  169. Enantiomeric separation of tramadol hydrochloride and its metabolites by cyclodextrin-mediated capillary zone electrophoresis